Literature DB >> 8778584

Partial liquid ventilation with perflubron in premature infants with severe respiratory distress syndrome. The LiquiVent Study Group.

C L Leach1, J S Greenspan, S D Rubenstein, T H Shaffer, M R Wolfson, J C Jackson, R DeLemos, B P Fuhrman.   

Abstract

BACKGROUND: The intratracheal administration of a perfluorocarbon liquid during continuous positive-pressure ventilation (partial liquid ventilation) improves lung function in animals with surfactant deficiency. Whether partial liquid ventilation is effective in the treatment of infants with severe respiratory distress syndrome is not known.
METHODS: We studied the efficacy of partial liquid ventilation with perflubron in 13 premature infants with severe respiratory distress syndrome in whom conventional treatment, including surfactant therapy, had failed. Partial liquid ventilation was initiated by instilling perflubron during conventional mechanical ventilation to a volume approximating the functional residual capacity. Infants were considered to have completed the study if they received partial liquid ventilation for at least 24 hours.
RESULTS: Ten infants received partial liquid ventilation for 24 to 76 hours. In the other three infants, partial liquid ventilation was discontinued within four hours in favor of high-frequency ventilation, which was not permitted by the protocol, and the data from these infants were excluded from the analysis. Within one hour after the instillation of perflubron, the arterial oxygen tension increased by 138 percent and the dynamic compliance increased by 61 percent; the mean (+/- SD) oxygenation index was reduced from 49 +/- 60 to 17 +/- 16. Chest radiographs showed symmetric filling, with patchy clearing during the return from partial liquid to gas ventilation. There were no adverse events clearly attributable to partial liquid ventilation. Infants were weaned from partial liquid to gas ventilation without complications. Eight infants survived to 36 weeks' corrected gestational age.
CONCLUSIONS: Partial liquid ventilation leads to clinical improvement and survival in some infants with severe respiratory distress syndrome who are not predicted to survive.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8778584     DOI: 10.1056/NEJM199609123351101

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  43 in total

1.  Liquid ventilation.

Authors:  Qutaiba A Tawfic; Rajini Kausalya
Journal:  Oman Med J       Date:  2011-01

Review 2.  Partial liquid ventilation.

Authors:  Mark C K Hamilton; Giles J Peek; Anthony E W Dux
Journal:  Pediatr Radiol       Date:  2005-09-09

Review 3.  Reactions in droplets in microfluidic channels.

Authors:  Helen Song; Delai L Chen; Rustem F Ismagilov
Journal:  Angew Chem Int Ed Engl       Date:  2006-11-13       Impact factor: 15.336

4.  Radiographic detection of perflubron fluoromediastinum and fluororetroperitoneum 9 years after partial liquid ventilation.

Authors:  R Daniel Hagerty; Michael P Phelan; Stuart C Morrison; Stephen F Hatem
Journal:  Emerg Radiol       Date:  2007-10-31

5.  Dual-Contrast 19F/1H Magnetic Resonance Imaging to Characterize Myocardial Infarct Healing.

Authors:  Gregory M Lanza
Journal:  Circ Cardiovasc Imaging       Date:  2018-11       Impact factor: 7.792

6.  Liquid dose pulmonary instillation of gentamicin PulmoSpheres formulations: tissue distribution and pharmacokinetics in rabbits.

Authors:  D J Smith; L M Gambone; T Tarara; D R Meays; L A Dellamary; C M Woods; J Weers
Journal:  Pharm Res       Date:  2001-11       Impact factor: 4.200

7.  Unsteady propagation of a liquid plug in a liquid-lined straight tube.

Authors:  Hideki Fujioka; Shuichi Takayama; James B Grotberg
Journal:  Phys Fluids (1994)       Date:  2008-06-24       Impact factor: 3.521

Review 8.  Liquid ventilation in the preterm neonate.

Authors:  C W Yoxall; N V Subhedar; N J Shaw
Journal:  Thorax       Date:  1997-08       Impact factor: 9.139

Review 9.  Current perspectives on the prevention and management of chronic lung disease in preterm infants.

Authors:  Prakesh S Shah
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

10.  Perflubron residua: 12 years following therapy.

Authors:  Sabah Servaes; Monica Epelman
Journal:  Pediatr Radiol       Date:  2009-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.